Essentials in Ophthalmology

G. K. Kriegstein  R. N. Weinreb
Series Editors

Glaucoma
Cataract and Refractive Surgery
Uveitis and Immunological Disorders
Vitreo-retinal Surgery
Medical Retina
Oculoplastics and Orbit
Pediatric Ophthalmology, Neuro-Ophthalmology, Genetics
Cornea and External Eye Disease
The series Essentials in Ophthalmology was initiated two years ago to expedite the timely transfer of new information in vision science and evidence-based medicine into clinical practice. We thought that this prospecient idea would be moved and guided by a resolute commitment to excellence. It is reasonable to now update our readers with what has been achieved.

The immediate goal was to transfer information through a high quality quarterly publication in which ophthalmology would be represented by eight subspecialties. In this regard, each issue has had a subspecialty theme and has been overseen by two internationally recognized volume editors, who in turn have invited a bevy of experts to discuss clinically relevant and appropriate topics. Summaries of clinically relevant information have been provided throughout each chapter.

Each subspecialty area now has been covered once, and the response to the first eight volumes in the series has been enthusiastically positive. With the start of the second cycle of subspecialty coverage, the dissemination of practical information will be continued as we learn more about the emerging advances in various ophthalmic subspecialties that can be applied to obtain the best possible care of our patients. Moreover, we will continue to highlight clinically relevant information and maintain our commitment to excellence.

G.K. Krieglstein
R. N. Weinreb
Series Editors
Clinicians and basic scientists from the fields of ophthalmology and vision research have made tremendous progress in understanding the pathogenesis of retinal diseases, developing novel diagnostic techniques, and instituting new treatments for retinal conditions.

This multi-authored volume provides concise updates on the relevant and most challenging topics in medical retina. It is a practical and useful publication that will help all ophthalmologists, whether in training or in practice, to manage patients with retinal diseases.

The first two chapters on microperimetry and scanning laser fundus imaging highlight the advances in diagnostic technology that have contributed significantly to our understanding of the pathophysiology and treatment of various diseases. The following chapters address the latest developments in the area of age-related macular degeneration including an update on genetic factors, current management strategies using anti-VEGF therapy, the role of combination treatments, and nutritional supplementation. The atrophic form of late AMD, i.e., geographic atrophy, is also addressed. Furthermore, current treatment approaches to diabetic macular edema and retinal vein occlusions are described. Finally, there is a discussion of the novel insights into Stargardt’s disease and idiopathic macular teleangiectasia, as well as perspectives on the expanding field of artificial vision.

Time and effort have been generously given by the contributing authors, to whom we, as editors, are extremely grateful. We are indebted to the editorial and production staff at Springer for their commitment to a timely publication in this rapidly moving field.

Frank G. Holz
Richard F. Spaide
# Contents

## Chapter 1  
**Microperimetry in Macular Disease**  
Klaus Rohrschneider

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1 Introduction</td>
<td>1</td>
</tr>
<tr>
<td>1.2 Instruments</td>
<td>2</td>
</tr>
<tr>
<td>1.2.1 Scanning Laser Ophthalmoscope</td>
<td>2</td>
</tr>
<tr>
<td>1.2.1.1 Fundus Perimetry (Microperimetry)</td>
<td>3</td>
</tr>
<tr>
<td>1.2.2 Micro Perimeter 1</td>
<td>4</td>
</tr>
<tr>
<td>1.2.2.1 Static Threshold Fundus Perimetry</td>
<td>4</td>
</tr>
<tr>
<td>1.2.2.2 Kinetic Fundus Perimetry</td>
<td>6</td>
</tr>
<tr>
<td>1.2.3 Comparison Between SLO Perimetry and MP 1</td>
<td>6</td>
</tr>
<tr>
<td>1.2.4 Accuracy of Fundus Perimetry</td>
<td>6</td>
</tr>
<tr>
<td>1.2.4.1 Static Threshold Perimetry</td>
<td>6</td>
</tr>
<tr>
<td>1.2.4.2 Kinetic Perimetry</td>
<td>7</td>
</tr>
<tr>
<td>1.2.5 Fundus-related Perimetry Versus Cupola Perimetry</td>
<td>7</td>
</tr>
<tr>
<td>1.3 Clinical Implementation</td>
<td>8</td>
</tr>
<tr>
<td>1.3.1 Macular Holes</td>
<td>8</td>
</tr>
<tr>
<td>1.3.2 Age-related Macular Degeneration</td>
<td>10</td>
</tr>
<tr>
<td>1.3.2.1 Geographic Atrophy of the RPE</td>
<td>10</td>
</tr>
<tr>
<td>1.3.2.2 Choroidal Neovascularization in AMD</td>
<td>10</td>
</tr>
<tr>
<td>1.3.3 Diabetic Retinopathy</td>
<td>10</td>
</tr>
<tr>
<td>1.3.4 Central Serous Chorioretinopathy</td>
<td>14</td>
</tr>
<tr>
<td>1.3.5 Stargardt's Disease</td>
<td>15</td>
</tr>
<tr>
<td>1.3.6 Vitelliform Macular Dystrophy (Best's Disease)</td>
<td>16</td>
</tr>
<tr>
<td>1.4 Conclusion</td>
<td>16</td>
</tr>
</tbody>
</table>

## Chapter 2  
**New Developments in cSLO Fundus Imaging**  
Giovanni Staurenghi, Grazia Levi, Silvia Pedenovi, Chiara Veronese

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Introduction</td>
<td>21</td>
</tr>
<tr>
<td>2.2 Near Infrared Imaging</td>
<td>22</td>
</tr>
<tr>
<td>2.2.1 Introduction</td>
<td>22</td>
</tr>
<tr>
<td>2.2.2 The Effect of Wavelength on Imaging in the Human Fundus</td>
<td>22</td>
</tr>
<tr>
<td>2.2.3 Comparison of Light Tissue Interactions for Visible and Near Infrared Wavelengths Using SLO</td>
<td>22</td>
</tr>
<tr>
<td>2.2.4 Mode of Imaging</td>
<td>22</td>
</tr>
<tr>
<td>2.2.5 Contrast of the Fundus</td>
<td>23</td>
</tr>
<tr>
<td>2.2.6 Fundus Features</td>
<td>23</td>
</tr>
<tr>
<td>2.2.7 Imaging of Pathological Features in Direct and Indirect Mode</td>
<td>23</td>
</tr>
<tr>
<td>2.3 Blue Autofluorescence Imaging</td>
<td>23</td>
</tr>
<tr>
<td>2.3.1 Autofluorescence and the Eye</td>
<td>24</td>
</tr>
<tr>
<td>2.3.1.1 Fluorescence of the Retinal Pigment Epithelium</td>
<td>24</td>
</tr>
<tr>
<td>2.3.1.2 How to Evaluate RPE Autofluorescence</td>
<td>24</td>
</tr>
<tr>
<td>2.3.2 Fundus Autofluorescence Changes in Early AMD</td>
<td>25</td>
</tr>
<tr>
<td>2.3.3 Fundus Autofluorescence Changes in Choroidal Neovascularization in AMD</td>
<td>26</td>
</tr>
<tr>
<td>2.3.4 Fundus Autofluorescence Changes in Geographic Atrophy in AMD</td>
<td>26</td>
</tr>
<tr>
<td>2.3.5 Fundus Autofluorescence in Acute and Chronic Recurrent Central Serous Chorioretinopathy</td>
<td>27</td>
</tr>
<tr>
<td>Section</td>
<td>Title</td>
</tr>
<tr>
<td>---------</td>
<td>-----------------------------------------------------------------------</td>
</tr>
<tr>
<td>2.3.6</td>
<td>Fundus Autofluorescence in Stargardt’s Macular Dystrophy-Fundus Flavimaculatus</td>
</tr>
<tr>
<td>2.3.7</td>
<td>Fundus Autofluorescence in Patients with Macular Holes</td>
</tr>
<tr>
<td>2.4</td>
<td>Wide-Field Contact Lens System</td>
</tr>
<tr>
<td>2.4.1</td>
<td>Introduction</td>
</tr>
<tr>
<td>2.4.2</td>
<td>Materials and Methods</td>
</tr>
<tr>
<td>2.4.2.1</td>
<td>Structure of a Wide-Field Contact Lens System</td>
</tr>
<tr>
<td>2.4.2.2</td>
<td>Limit and Advantage of a Wide-Field Contact Lens System</td>
</tr>
<tr>
<td>2.4.3</td>
<td>Other Techniques of Execution of Wide-field Fluorescein Angiograms</td>
</tr>
<tr>
<td>2.4.4</td>
<td>Clinical Application</td>
</tr>
</tbody>
</table>

**Chapter 3**

**Genetics of Age-Related Macular Degeneration: Update**

Hendrik P.N. Scholl, Monika Fleckenstein, Peter Charbel Issa, Claudia Keilhauer, Frank G. Holz, Bernhard H.F. Weber

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1</td>
<td>Introduction: Genetic Influence on AMD</td>
<td>35</td>
</tr>
<tr>
<td>3.2</td>
<td>Analysis of Candidate Genes for AMD</td>
<td>36</td>
</tr>
<tr>
<td>3.3</td>
<td>Linkage and Association Studies in AMD</td>
<td>38</td>
</tr>
<tr>
<td>3.4</td>
<td>Complement Factor H Gene LOC387715</td>
<td>43</td>
</tr>
<tr>
<td>3.5</td>
<td>Factor B</td>
<td>44</td>
</tr>
<tr>
<td>3.6</td>
<td>Gene–Gene and Gene–Environment Interaction in AMD</td>
<td>45</td>
</tr>
<tr>
<td>3.8</td>
<td>Conclusions</td>
<td>46</td>
</tr>
</tbody>
</table>

**Chapter 4**

**Anti-VEGF Treatment for Age-Related Macular Degeneration**

Todd R. Klesert, Jennifer I. Lim

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>Basic Science</td>
<td>53</td>
</tr>
<tr>
<td>4.1.1</td>
<td>Historical Perspective</td>
<td>53</td>
</tr>
<tr>
<td>4.1.2</td>
<td>VEGF Isoforms</td>
<td>54</td>
</tr>
<tr>
<td>4.1.3</td>
<td>VEGF Expression</td>
<td>54</td>
</tr>
<tr>
<td>4.1.4</td>
<td>VEGF Receptors</td>
<td>54</td>
</tr>
<tr>
<td>4.1.5</td>
<td>VEGF Activity</td>
<td>55</td>
</tr>
<tr>
<td>4.2</td>
<td>Current Anti-VEGF Therapies</td>
<td>55</td>
</tr>
<tr>
<td>4.2.1</td>
<td>Aptamers: Pegaptanib Sodium (Macugen)</td>
<td>55</td>
</tr>
<tr>
<td>4.2.2</td>
<td>Monoclonal Antibodies:</td>
<td>56</td>
</tr>
<tr>
<td>4.2.3</td>
<td>Anti-VEGF Therapy: Practical Considerations</td>
<td>60</td>
</tr>
<tr>
<td>4.3</td>
<td>Intraocular Injection Technique</td>
<td>61</td>
</tr>
<tr>
<td>4.3.1</td>
<td>Safety Considerations</td>
<td>60</td>
</tr>
<tr>
<td>4.3.2</td>
<td>Bevacizumab (Avastin)</td>
<td>61</td>
</tr>
<tr>
<td>4.3.3</td>
<td>Preparation: Compounding Pharmacies</td>
<td>61</td>
</tr>
<tr>
<td>4.3.4</td>
<td>Future Anti-VEGF Therapies</td>
<td>61</td>
</tr>
<tr>
<td>4.3.5</td>
<td>Small Interfering RNAs</td>
<td>62</td>
</tr>
<tr>
<td>4.3.6</td>
<td>Receptor Tyrosine Kinase Inhibitors</td>
<td>63</td>
</tr>
<tr>
<td>4.5</td>
<td>Conclusion</td>
<td>64</td>
</tr>
</tbody>
</table>

**Chapter 5**

**Intravitreal Injections: Techniques and Sequelae**

Heinrich Heimann

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.1</td>
<td>Introduction</td>
<td>67</td>
</tr>
<tr>
<td>5.2</td>
<td>Complications of Intravitreal Injections</td>
<td>68</td>
</tr>
<tr>
<td>5.2.1</td>
<td>Methodology</td>
<td>69</td>
</tr>
<tr>
<td>5.2.2</td>
<td>Perioperative Complications</td>
<td>69</td>
</tr>
<tr>
<td>5.2.2.1</td>
<td>Conjunctival Hemorrhage</td>
<td>69</td>
</tr>
<tr>
<td>5.2.2.2</td>
<td>Conjunctival Scarring</td>
<td>72</td>
</tr>
<tr>
<td>5.2.2.3</td>
<td>Pain</td>
<td>72</td>
</tr>
<tr>
<td>5.2.2.4</td>
<td>Punctate Keratitis and Corneal Edema</td>
<td>72</td>
</tr>
<tr>
<td>5.2.2.5</td>
<td>Vitreous Reflux</td>
<td>72</td>
</tr>
<tr>
<td>5.2.2.6</td>
<td>Traumatic Cataract</td>
<td>72</td>
</tr>
<tr>
<td>5.2.2.7</td>
<td>Cataract Progression</td>
<td>73</td>
</tr>
<tr>
<td>5.2.2.8</td>
<td>Retinal Perforation</td>
<td>73</td>
</tr>
<tr>
<td>5.2.2.9</td>
<td>Vitreous Floaters</td>
<td>74</td>
</tr>
<tr>
<td>5.2.2.10</td>
<td>Vitreous Hemorrhage</td>
<td>74</td>
</tr>
<tr>
<td>5.2.2.11</td>
<td>Retinal Toxicity</td>
<td>74</td>
</tr>
<tr>
<td>5.2.2.12</td>
<td>Intraocular Inflammation</td>
<td>74</td>
</tr>
</tbody>
</table>
8.4 Risk Factors .......................... 118
  8.4.1 Genetic Factors ................. 118
  8.4.2 Systemic Risk Factors .......... 118
  8.4.3 Ocular Risk Factors ............. 119
8.5 Development of CNV in Eyes with GA .................. 122
8.6 Visual Function in GA Patients .................. 123
  8.6.1 Measurement of Visual Acuity .......... 123
  8.6.2 Contrast Sensitivity .............. 124
  8.6.3 Reading Speed ................... 124
  8.6.4 Fundus Perimetry .................. 124

Chapter 9
Diabetic Macular Edema: Current Treatments
Florian K.P. Sutter, Mark C. Gillies, Horst Helbig

9.1 Introduction .................. 131
9.2 Epidemiology .................. 131
9.3 Pathophysiology ............... 132
9.4 Diabetic Macular Edema and Laboratory Science ........ 132
9.5 Quality of Life .................. 133
9.6 Diagnosis and Screening ....... 133
9.7 Types of Diabetic Macular Edema .................. 134
  9.7.1 Clinically Significant Macular Edema ........ 134
  9.7.2 Focal Diabetic Macular Edema .......... 134
  9.7.3 Diffuse Diabetic Macular Edema .......... 134
  9.7.4 Cystoid Macular Edema ............. 134
  9.7.5 Ischemic Macular Edema .......... 134
  9.7.6 OCT Patterns of Diabetic Macular Edema .......... 134
9.8 Treatment .................. 135
  9.8.1 Systemic Treatment .......... 135
  9.8.1.1 Glycemic Control .......... 135
  9.8.1.2 Blood Pressure Control .......... 135
  9.8.1.3 Reducing Levels of Blood Lipids .......... 135
  9.8.1.4 Treatment of Renal Dysfunction and Anemia .......... 136
  9.8.1.5 Smoking .......... 136
  9.8.2 Systemic Pharmacotherapy .......... 136
  9.8.2.1 PKC-β Inhibitors .......... 136
  9.8.2.2 Aldose Reductase and AGE Inhibitors .......... 136
  9.8.2.3 Antioxidants .......... 136
  9.8.3 A Team Approach to the Prevention of Loss of Vision in People with Diabetes .......... 137
  9.8.4 Local Ophthalmic Treatment .......... 138
  9.8.4.1 Focal Macular Laser .......... 138
  9.8.4.2 Grid Macular Laser .......... 138
  9.8.4.3 Recent Trends in Macular Laser Therapy .......... 138
  9.8.4.4 Micropulsed, Sub-threshold "Selective" Laser Therapy .......... 139
  9.8.4.5 Vitrectomy .......... 139
  9.8.4.6 Intravitreal Steroids .......... 139
  9.8.4.7 Periocular Steroids .......... 140
  9.8.4.8 Intravitreal Anti-VEGF Antibodies .......... 140
  9.8.4.9 Cataract Surgery .......... 141
9.9 Current Clinical Practice/Recommendations .......... 141

Chapter 10
Treatment of Retinal Vein Occlusions
Rajeev S. Ramchandran, R. Keith Shuler, Sharon Fekrat

10.1 Introduction .................. 147
10.2 Pathophysiology ............... 148
10.3 Branch and Central Vein Occlusion Studies .......... 148
  10.3.1 Background .......... 148
  10.3.2 Branch Vein Occlusion Study .......... 149
  10.3.3 Central Vein Occlusion Study .......... 149
10.4 Systemic Pharmacologic Treatments .......... 150
10.5 Targeting Macular Edema .......... 151
10.6 Intravitreal Pharmacotherapy .......... 151
  10.6.1 Background .......... 151
  10.6.2 Intravitreal Triamcinolone: BRVO .......... 153
  10.6.3 Intravitreal Triamcinolone: CRVO .......... 153
  10.6.4 Fluocinolone Acetonide Intravitreal Implant .......... 153
Chapter 12

Idiopathic Macular Telangiectasia

Peter Charbel Issa, Hendrik P.N. Scholl, Hans-Martin Helb, Frank G. Holz

12.1 Introduction .................. 183
12.2 Type 1 Idiopathic Macular Telangiectasia ............. 183
12.2.1 Epidemiology ............... 183
12.2.2 Diagnostic Approach and Clinical Findings .......... 185
12.2.3 Functional Implications ........ 185
12.2.4 Pathophysiological Considerations .......... 186
12.2.5 Therapy .......... 186
12.3 Type 2 Idiopathic Macular Telangiectasia ............. 187
12.3.1 Epidemiology ............... 188
12.3.2 Diagnostic Approach and Clinical Findings .......... 188
12.3.3 Functional Implications .... 189
12.3.4 Associated Diseases ........... 192
12.3.5 Pathophysiological Considerations .......... 192
12.3.6 Therapeutic Approaches .......... 193
12.4 Type 3: Idiopathic Macular Telangiectasia .......... 194
12.5 Perspectives ............. 194

Chapter 13

Artificial Vision

Peter Walter

13.1 Introduction .................. 199
13.3 Interfacing the Neurons .......... 200
13.3.1 Epiretinal Stimulation .......... 201
13.3.2 Subretinal Approach .......... 203
13.3.3 Transchoroidal, Transscleral, and Suprachoroidal Stimulation .......... 203
13.3.4 Optic Nerve Approach .......... 204
13.3.5 Cortical Prosthesis .......... 204
13.4 Pixel Vision and Filters .......... 204
13.5 Outlook .................. 206
13.6 Conclusion .................. 206

Subject Index .................. 211
Contributors

Peter Charbel Issa, Dr.
Department of Ophthalmology
University of Bonn
Ernst-Abbe-Straße 2
53127 Bonn
Germany

Emily Y. Chew, MD
National Eye Institute/National Institutes of Health
10 Center Drive
Bethesda, MD 20892-1204
USA

Hanna R. Coleman, MD
National Eye Institute/National Institutes of Health
10 Center Drive
Bethesda, MD 20892-1204
USA

Sharon Fekrat, MD, FACS
Department of Ophthalmology
Duke University Medical Center
Durham, NC 27710
USA

Monika Fleckenstein, Dr.
Department of Ophthalmology
University of Bonn
Ernst-Abbe-Straße 2
53127 Bonn
Germany

Mark C. Gillies, MD
Save Sight Institute
P.O. Box 4337
Sydney NSW 2001
Australia

Heinrich Heimann, Priv.-Doz. Dr.
Consultant Ophthalmic Surgeon
St. Paul’s Eye Unit, Royal Liverpool University Hospital
Prescot Street
Liverpool, L7 8XP
UK

Hans-Martin Helb, Dr.
Department of Ophthalmology
University of Bonn
Ernst-Abbe-Straße 2
53127 Bonn
Germany

Horst Helbig, Prof. Dr.
Department of Ophthalmology
University of Regensburg
Franz-Josef-Strauß-Allee 11
93042 Regensburg
Germany

Frank G. Holz, Prof. Dr.
Department of Ophthalmology
University of Bonn
Ernst-Abbe-Straße 2
53127 Bonn
Germany

Claudia Keilhauer, Dr.
Department of Ophthalmology
University of Würzburg
Josef-Schneider-Straße 11
97080 Würzburg
Germany

Todd R. Klesert, MD, PhD
Doheny Retina Institute of the Doheny Eye Institute
USC Keck School of Medicine
1450 San Pablo Street
Los Angeles, CA 90027
USA
Grazia Levi, MD  
II Scuola di Specialità in Oftalmologia  
Università degli studi di Milano  
Facoltà di Medicina e Chirurgia  
Dipartimento di Scienze Cliniche Luigi Sacco  
Via G.B. Grassi, 74  
20157 Milano  
Italy

Jennifer I. Lim, MD  
Doheny Eye Institute  
USC Keck School of Medicine  
1450 San Pablo Street  
Los Angeles, CA 90033  
USA

Noemi Lois, MD, PhD  
Aberdeen Royal Infirmary  
University Hospital Foresterhill  
Aberdeen AB25 2ZN  
UK

Silvia Pedenovi, MD  
II Scuola di Specialità in Oftalmologia  
Università degli studi di Milano  
Facoltà di Medicina e Chirurgia  
Dipartimento di Scienze Cliniche Luigi Sacco  
Via G.B. Grassi, 74  
20157 Milano  
Italy

Rajeev S. Ramchandran, MD  
Department of Ophthalmology  
Duke University Medical Center  
Durham, NC 27710  
USA

Klaus Rohrschneider, Prof. Dr.  
Department of Ophthalmology  
University of Heidelberg  
Im Neuenheimer Feld 400  
69120 Heidelberg  
Germany

Steffen Schmitz-Valckenberg, Dr.  
Department of Ophthalmology  
University of Bonn  
Ernst-Abbe-Straße 2  
53127 Bonn  
Germany

Hendrik PN. Scholl, Priv.-Doz. Dr.  
Department of Ophthalmology  
University of Bonn  
Ernst-Abbe-Straße 2  
53127 Bonn  
Germany

R. Keith Shuler, MD  
Department of Ophthalmology  
Duke University Medical Center  
Durham, NC 27710  
USA

Richard F. Spaide, MD, Prof.  
Vitreous, Retina, and Macula Consultants of New York,  
and LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear, and Throat Hospital  
460 Park Avenue  
New York, NY 10022  
USA

Giovanni Staurenghi, MD, Prof.  
Cattedra di Clinica Oculistica  
II Scuola di Specialità in Oftalmologia  
Università degli studi di Milano  
Facoltà di Medicina e Chirurgia  
Dipartimento di Scienze Cliniche Luigi Sacco  
Via G.B. Grassi, 74  
20157 Milano  
Italy

Florian K.P. Sutter, Priv.-Doz. Dr.  
Department of Ophthalmology  
University of Zurich  
Rämistrasse 100  
8049 Zurich  
Switzerland
Chiara Veronese, MD
II Scuola di Specialità in Oftalmologia
Università degli studi di Milano
Facoltà di Medicina e Chirurgia
Dipartimento di Scienze Cliniche Luigi Sacco
Via G.B. Grassi, 74
20157 Milano
Italy

Peter Walter, Prof. Dr.
Department of Ophthalmology
RWTH Aachen University
Pauwelsstraße 30
52074 Aachen
Germany

Bernhard H.F. Weber, Prof. Dr.
Institute for Human Genetics
University of Regensburg
Franz-Josef-Strauß-Allee 11
93053 Regensburg
Germany